The invention relates to a compound having the formula I ##STR1## wherein R.sup.1 is hydroxy, (1-6C)alkoxy or NR.sup.4 R.sup.5, R.sup.4 and R.sup.5 being independently hydrogen, (1-6C)alkyl, (3-7C)cycloalkyl, (2-6C)alkenyl, (4-6C)aryl or (5-7C)aralkyl, the aryl groups of which may be optionally substituted with halogen, (1-6C)alkyl or (1-6C)alkoxy; R.sup.2 is a halo atom, (1-8C)acyloxy, --O--C(O)--O-(1-6C)alkyl, --O--C(O)--O-(5-7C)aralkyl, --SR.sup.6, --S(O)R.sup.6, --SeR.sup.6 or --Se(O)R.sup.6...

The present invention is based upon a general principle of providing specific oligonucleotide segments ("linkers", herein) to be attached in sequence to a cloned DNA coding segment. The linkers of the present invention confer desired functional properties on the expression of the protein coded by the coding sequence. Using linkers of the present invention, the desired protein may be expressed either as a fusion or non-fusion protein. A linker coding for an additional sequence of amino acids may ...

The present invention provides a method for identifying, isolating, mapping, amplifying and sequencing DNA fragments using sets of indexing linkers. Panels of indexing linkers and kits are also provided.

Synthetic nucleic acid molecules are provided which are called indexing linkers and which can be selectively linked to unknown, or non-identical cohesive ends of nucleic acid fragments. Such indexing linkers are useful for the selective isolation, identification, amplification, labelling, and modification, of nucleic acid fragments, especially subsets of such fragments released by cleavage using Type IIS restriction endonucleases or restriction endonucleases recognizing interrupted palindromic s...

Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.

The invention relates to dithiane adducts of substituted benzoins and substituted benzoins derived therefrom each of which are useful as protecting groups, photolabile linkers, and fluorescent probes.

Conjugates containing a targeting ligand, such as an antibody, a therapeutically active drug and a branched peptide linker. The branched peptide linker contains two or more amino acid moieties that provide an enzyme cleavage site. The number of drugs capable of being bonded to the branched linkers varies by a factor of two for each generation of branching.

This application provides frame-adjusting linkers FAL-1 and FAL-2 which are single-stranded DNA consisting of a palindrome base sequence of SEQ ID NO. 1 and SEQ ID NO. 2, respectively. These linkers are able to prepare mutant DNA sequences having correct translation frames before and behind the any cleaved sites, therefore, time and cost for preparation of mutant protein, etc. can be greatly reduced.

Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.

In various embodiments of the invention, novel compositions having a polynucleotide bound to a substrate via a cleavable linker are provided, and methods of cleaving a polynucleotide from a substrate are provided.